麦澜德(688273) - 投资者关系活动记录表（2024年12月5日）

Group 1: Financial Performance - In the first three quarters of 2024, the company achieved a revenue of approximately 330 million CNY, representing a year-on-year growth of 13.81% [2] - The net profit attributable to the parent company was approximately 96.07 million CNY, with a year-on-year increase of 13.37% [3] Group 2: Business Development Directions - The future business development and growth logic are primarily driven by three segments: pelvic floor rehabilitation, reproductive anti-aging, and rehabilitation [3] - The pelvic floor segment is experiencing increasing demand due to the aging population and rising health awareness, with a growing number of women actively screening and treating pelvic floor dysfunction [3] - The reproductive anti-aging segment has formed an integrated ecosystem since the launch of its first product in 2022, generating over 50 million CNY in revenue in the first half of 2024 [4] Group 3: Product Innovations - The company launched the "Magnetic-Electric Thermal Imaging · Smart Integration PI-ONE" system in the first quarter, which includes three new products for pelvic floor rehabilitation [6] - The new pelvic floor rehabilitation products aim to provide a comprehensive solution, integrating various technologies for personalized treatment plans [7] Group 4: Market Strategy - The company plans to continue focusing on women's health and beauty, actively expanding into new technologies, products, markets, and business areas [5] - Despite a slowdown in the overall growth of the pelvic floor rehabilitation industry, the company has maintained a relatively stable growth rate compared to peers, indicating a strong market position [5] Group 5: Revenue Composition - Revenue from consumables accounts for approximately 25% of total revenue, with a stable gross margin [7]